Search

Displaying results 3661 - 3670 of 10000 in total
  1. Drug

    Omapatrilat

    go.drugbank.com/drugs/DB00886
    Experimental

    This drug from BMS was not approved by the FDA due to angioedema safety concerns. … Omapatrilat is an investigational drug that inhibits both neutral endopeptidase (NEP) and angiotensin converting enzyme (ACE).

    Categories: Agents Acting on the Renin-Angiotensin System, Heterocyclic Compounds, 1-Ring
  2. Drug

    Aspergillus fumigatus

    go.drugbank.com/drugs/DB10425
    Approved

    Aspergillus fumigatus is a fungus which can provoke allergic reactions. Aspergillus fumigatus extract is used in allergenic testing.

    Mixtures: Number Ten Mold Mixture, Number Ten Mold Mixture
  3. Drug

    Cochliobolus sativus

    go.drugbank.com/drugs/DB10433
    Approved

    Cochliobolus sativus is a fungus which can provoke allergic reactions. Cochliobolus sativus extract is used in allergenic testing.

    Mixtures: Number Ten Mold Mixture, Number Ten Mold Mixture
  4. Drug

    Cat dander extract

    go.drugbank.com/drugs/DB13904
    Approved

    It is used in the diagnosis and treatment (immunotherapy) of patients with a history of allergy to cats. … An allergic reaction to cats is induced by the presence of antigen-specific IgE antibodies that are bound to specific receptors on mast cells and basophils.

  5. Drug

    Tipiracil

    go.drugbank.com/drugs/DB09343
    ApprovedInvestigational

    Tipiracil is a thymidine phosphorylase inhibitor. It is used in combination with trifluridine, in a ratio of 1:0.5, to form TAS-102. … The main function of Tipiracil in TAS-102 is to increase trifluridine bioavailability by inhibiting its catabolism.

    Synonyms: 5-chloro-6-(2-iminopyrrolidin-1-yl)methyl-2,4(1H,3H)-pyrimidinedione, 5-chloro-6-[(2-iminopyrrolidin-1-yl)methyl]-1H-pyrimidine-2,4-dioneCategories: MATE 1 Substrates with a Narrow Therapeutic Index, MATE 1 Substrates
  6. Drug

    Benznidazole

    go.drugbank.com/drugs/DB11989
    ApprovedInvestigational

    [L939] It is the first treatment made available in the United States for Chagas disease. … Benznidazole was granted accelerated approval for the treatment of Chagas disease in children 2-12 years of age by the FDA on August 29, 2017.

    Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesProducts: ABALEA ®100 MG
  7. Drug

    Duvelisib

    go.drugbank.com/drugs/DB11952
    ApprovedInvestigational

    Duvelisib, also known as IPI-145 and INK-1197, is a small-molecule inhibitor of phosphoinositide-3 kinases that was designed initially to prove that simultaneous inhibition of the isoforms delta and gamma … All the work around duvelisib showed that this agent is a potent inhibitor of both forms.[A39025] Duvelisib was developed by Verastem, Inc and FDA approved on September 24, 2018.[L4585]

    Categories: P-glycoprotein substrates, Cytochrome P-450 Substrates
  8. Drug

    Phenylbutyric acid

    go.drugbank.com/drugs/DB06819
    ApprovedInvestigational

    [A249035] It is used to treat genetic metabolic syndromes, neuropathies, and urea cycle disorders.[L386,L42105] … It demonstrates a number of cellular and biological effects, such as relieving inflammation and acting as a chemical chaperone.

    Synonyms: 4-Phenyl-n-butyric acid, γ-Phenyl-n-butyric acidCategories: Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 Enzyme Inhibitors
  9. Drug

    Vimseltinib

    go.drugbank.com/drugs/DB17520
    ApprovedInvestigational

    [A265035] It is intended to provide a safer alternative to [pexidartinib], a previously approved CSF1R inhibitor associated with significant liver toxicity - the greater selectivity of vimseltinib results … [L52230,A265035] Vimseltinib - under the brand name Romvimza - was approved by the FDA in February 2025 for the treatment of tenosynovial giant cell tumours for which surgical resection is not appropriate

    Categories: MATE 1 Inhibitors, MATE 2 InhibitorsSynonyms: 2-(isopropylamino)-3-methyl-5-(6-methyl-5-((2-(1-methyl-1h-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)pyrimidin-4(3h)-one, 3-methyl-2-((1-methylethyl)amino)-5-(6-methyl-5-((2-(1-methyl-1h-pyrazol-4-yl)-4-pyridinyl)oxy)-2-pyridinyl)-4(3h)-pyrimidinone
  10. Drug

    Blonanserin

    go.drugbank.com/drugs/DB09223
    Investigational

    As a second-generation (atypical) antipsychotic, it is significantly more efficacious in the treatment of the negative symptoms of schizophrenia compared to first-generation (typical) antipsychotics. … It offers improved tolerability as it lacks side effects such as extrapyramidal symptoms, excessive sedation, or hypotension.

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Cytochrome P-450 Substrates